Paul Massman

Paul Massman

Auto-generated profile, based on publicly available information

Paul Massman

Department of Psychology, University of Houston, 126 Heyne Building, Houston, TX 77204-5022, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2010 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
RDRachelle S Doody
Rachelle S Doody
VPValory Pavlik
Valory Pavlik
PMPaul Massman
Paul Massman
SRSusan Rountree
Susan Rountree
EDEveleen Darby
Eveleen Darby
WCWenyaw Chan
Wenyaw Chan
Introduction: Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate to see whether it predicted performance on cognition, function and behavior over time, and to see whether it predicted survival. Methods: We used standardized approaches to assess baseline characteristics and to estimate disease duration, and calculated the initial (pre-progression) rate in 597 AD patients followed for up to 15 years. We designated slow, intermediate and rapidly progressing groups. Using mixed effects regression analysis, we examined the predictive value of a pre-progression group for longitudinal performance on standardized measures. We used Cox survival analysis to compare survival time by progression group. Results: Patients in the slow and intermediate groups maintained better performance on the cognitive (ADAScog and VSAT), global (CDR-SB) and complex activities of daily living measures (IADL) (P values < 0.001 slow versus fast; P values < 0.003 to 0.03 intermediate versus fast). Interaction terms indicated that slopes of ADAScog and PSMS change for the slow group were smaller than for the fast group, and that rates of change on the ADAScog were also slower for the intermediate group, but that CDR-SB rates increased in this group relative to the fast group. Slow progressors survived longer than fast progressors (P = 0.024). Conclusions: A simple, calculated progression rate at the initial visit gives reliable information regarding performance over time on cognition, global performance and activities of daily living. The slowest progression group also survives longer. This baseline measure should be considered in the design of long duration Alzheimer's disease clinical trials.

18 May 2010 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
RDRachelle S Doody
Rachelle S Doody
VPValory Pavlik
Valory Pavlik
PMPaul Massman
Paul Massman
SRSusan Rountree
Susan Rountree
EDEveleen Darby
Eveleen Darby
WCWenyaw Chan
Wenyaw Chan
It has been brought to our attention that Figure 7 in our recently published paper [1] contains a labeling error. Th e group marked "slow" should be labeled "fast" and the group marked "fast" should be labeled "slow". Th e corrected fi gure 7 is given here as Figure 1.